Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of miR-145-3p in preparing medicines for preventing or treating multiple myeloma disease

A multiple myeloma, drug technology, applied in the field of clinical application of miR-145-3p and its analogs, to achieve the effect of promoting cell apoptosis

Active Publication Date: 2017-02-22
SECOND AFFILIATED HOSPITAL SECOND MILITARY MEDICAL UNIV
View PDF12 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is also no literature report on the relationship between miR-145-3p and multiple myeloma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of miR-145-3p in preparing medicines for preventing or treating multiple myeloma disease
  • Application of miR-145-3p in preparing medicines for preventing or treating multiple myeloma disease
  • Application of miR-145-3p in preparing medicines for preventing or treating multiple myeloma disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0074] Example 1, microRNAs expression analysis and verification in MM patients

[0075] There are many kinds of microRNAs in the peripheral plasma of MM patients. In this experiment, the classic microarray screening method was used to screen the microRNAs differentially expressed in MM patients and normal controls.

[0076] The criteria for our selection of patients are as follows: all 30 patients with multiple myeloma were inpatients in Shanghai Changzheng Hospital (21 males and 9 females, aged 40-74 years, median 60 years old, ISS stage 2 stage and stage 3 patients), and the hospitalization time was from February 2013 to July 2014. These patients all met the diagnostic criteria for multiple myeloma recommended by NCCN in 2013: (1) tissue biopsy or bone marrow smear: plasma cells>30 %, often accompanied by morphological changes; (2) Monoclonal immunoglobulin (M protein): IgG>35g / L, IgA>20g / L, IgM>15g / L, IgD>2g / L, IgE>2g / L , monoclonal K or lambda light chain in urine > 1g / ...

Embodiment 2

[0083] Example 2, the value of miR-145-3p in clinical parameters and prognosis

[0084] Serum collection from patients and detection of clinical parameters: After collecting serum from MM patients in a sampling tube without anticoagulant, leave it for a period of time, centrifuge at 3500 rpm for 10 minutes, and collect the supernatant for later use. For the detection of various clinical indicators, albumin is detected by BCG colorimetric method, β2-MG is detected by immunoturbidimetric method, creatinine is detected by colorimetric method, Ca 2+ Visible absorbance photometry method was used for detection.

[0085] Collection of patient clinical prognosis information: Obtain patient survival information through follow-up and other methods.

[0086] Statistical methods: We used correlation analysis and Kaplan-Meier survival analysis to analyze the clinical application value of miR-145-3p.

[0087] The result is as figure 2 As shown, the correlation analysis results between t...

Embodiment 3

[0088] Example 3, miR-145-3p overexpression induces increased cell apoptosis

[0089] MM cell culture: Human myeloma cell line LP-1 (purchased from the Institute of Cells, Chinese Academy of Sciences) was cultured under conventional conditions, that is, in a 37°C, 5% carbon dioxide incubator, and the medium contained 10% fetal bovine serum (FBS) and 1% Double antibody (penicillin 100U / ml and streptomycin 0.1mg / ml) 1640.

[0090] MiR-145-3p analogs and their inhibitors were designed and synthesized by Guangzhou Ruibo Biotechnology Co., Ltd., and then transfected:

[0091] miR-145-3p mimic, the sequence is shown in SEQ ID NO:1;

[0092] miR-145-3p inhibitor, the sequence is 5'-AGAACAGUAUUUCCAGGAAUCC-3' (SEQ ID NO: 2);

[0093] Adjust the LP-1 cells to the best state, adjust the concentration after counting, and the cell density is 1x10 5 / ml; pipette 2.5μl miR-145-3p mimic / inhibitors into 100ul Opti-MEM, and mix gently. At the same time, set up a transfection control to ensu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of biological medicines. According to the invention, peripheral plasma of a patient with multiple myeloma is subjected to microRNAs expression profile analysis, and based upon qPCR technical verification, it discovers that the expression level of miR-145-3p in the peripheral plasma of the patient with the multiple myeloma is significantly reduced in comparison that in normal and healthy people. In addition, by conducting miR-145-3p over-expression and miR-145-3p silencing and by observing cell apoptosis and autophagy levels, results show that the miR-145-3p is capable of promoting cell apoptosis and autophagy. The invention provides a novel serum marker for the diagnosis of the multiple myeloma disease and also provides a novel target for the prevention and treatment of the multiple myeloma disease.

Description

technical field [0001] The present invention relates to the technical field of biomedicine, more specifically, relates to the clinical application of miR-145-3p and its analogues. Background technique [0002] MicroRNA is a kind of small molecule RNA with post-transcriptional regulatory activity discovered in Drosophila, nematode, mouse and human in recent years. The discovery of a large number of endogenous small RNAs benefits from two technologies, one is the construction and sequencing of microRNA cDNA libraries; the other is the capture of biotin-labeled oligonucleotide probes, which are A technique for performing PCR amplification. Through library construction and sequencing, people have mastered a large amount of microRNA sequence information, and through bioinformatics comparison analysis of these sequences, it has been found that most microRNAs are highly conserved among species and highly homologous in evolution. [0003] Bioinformatics analysis found that a micro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7105A61P35/00C12Q1/68A61K31/573
CPCA61K31/573A61K31/7105C12Q1/6886C12Q2600/136C12Q2600/158C12Q2600/178A61K2300/00
Inventor 周琳吴洪坤刘畅王皓殷杏吴雯李江燕
Owner SECOND AFFILIATED HOSPITAL SECOND MILITARY MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com